Document is current
Any future updates will be listed below
-
Authors
Labbé, David P. https://orcid.org/0000-0001-8864-8765
Zadra, Giorgia https://orcid.org/0000-0002-8123-1358
Yang, Meng
Reyes, Jaime M. https://orcid.org/0000-0001-7895-2472
Lin, Charles Y.
Cacciatore, Stefano https://orcid.org/0000-0001-7052-7156
Ebot, Ericka M.
Creech, Amanda L.
Giunchi, Francesca
Fiorentino, Michelangelo
Elfandy, Habiba
Syamala, Sudeepa
Karoly, Edward D.
Alshalalfa, Mohammed
Erho, Nicholas
Ross, Ashley
Schaeffer, Edward M.
Gibb, Ewan A.
Takhar, Mandeep
Den, Robert B.
Lehrer, Jonathan
Karnes, R. Jeffrey
Freedland, Stephen J.
Davicioni, Elai
Spratt, Daniel E.
Ellis, Leigh https://orcid.org/0000-0003-4739-5049
Jaffe, Jacob D. https://orcid.org/0000-0001-9845-1210
DʼAmico, Anthony V.
Kantoff, Philip W.
Bradner, James E. https://orcid.org/0000-0002-2718-4415
Mucci, Lorelei A.
Chavarro, Jorge E.
Loda, Massimo
Brown, Myles
-
Funding
Funding for this research was provided by:
Prostate Cancer Foundation
Cancer Research Society
U.S. Department of Defense
Dana-Farber Cancer Institute
National Institute of Health; National Cancer Institute
- License Information
-
More Information
Article History
Received: 6 September 2018
Accepted: 23 August 2019
First Online: 25 September 2019
Competing interests
: C.Y.L. receives sponsored research from and consults for Kronos Bio, is a shareholder and inventor of IP licensed to Syros Pharmaceuticals, is a shareholder of Amgen, and is an equity partner of Cambridge Science Corporation. M.A., N.E., M.T., J.L., E.A.G. and E.D. are employees of Decipher Biosciences. E.D.K. is currently employed of Metabolon. M.B. receives sponsored research support from Novartis. M.B. is a consultant to Aleta Biotherapeutics and H3 Biomedicine and serves on the SAB of Kronos Bio. The remaining authors declare no competing interests.
